We found a significant relationship between RR and MST in clinical trials with EGFR-TKIs. RR could be an independent surrogate marker for MST in the current response criteria in the clinical trials of EGFR-TKIs.
Background: Recently, multiple-line chemotherapy has become popular for non-small cell lung cancer (NSCLC). The survival time of patients is influenced by patient characteristics and subsequent treatments. Methods: The usefulness of paclitaxel plus S1 (PTX+S1) was evaluated in 46 pretreated NSCLC patients. Time from the start of individual regimens till the start of the next one (TNR) was calculated for regimens administered to the study population including PTX+S1 and analyzed by the shared frailty Cox model. Results: The response rate and the median progression-free survival time of PTX+S1 were 32.6% and 253 days, respectively. Substantial difference in TNR was observed in epidermal growth factor receptor mutation status and in line and type of regimens, but not in stage, age, sex, performance status and histology, by univariate analysis. Multivariate analysis revealed that PTX+S1 was only one factor to prolong TNR. Conclusion: Because of long progression-free survival and long TNR, further evaluation of PTX+S1 is necessary.
A 56-year-old woman with Hodgkin-like adult T-cell leukemia/lymphoma was treated with allogeneic peripheral blood stem cell transplantation on 17 April 2009. She manifested a moderate fever on day 41. CT scanning and other examinations detected slightly swollen lymph nodes, and pathological findings of right axillary lymph nodes revealed an Epstein-Barr virus-associated post-transplant lymphoproliferative disorder. She was successfully treated with rituximab.
number of fair to good quality blastocysts and utilization rates of blastocysts. This study is unique from prior studies in that 96.4% of study patients underwent antagonist stimulation cycles with GnRH agonist trigger. DESIGN: Prospective cohort study. MATERIALS AND METHODS: All patients underwent IVF / ICSI between August 2016 and February 2017 at a tertiary academic fertility centre. All patients included were normal responders with > 8 mature follicles (> 17 mm) at retrieval. All patients were assigned to alternate ovarian (left or right) flushing on an alternating day allocation. Each patient was used as their own control comparing the ovary with the aspirated and flushed follicles to the contralateral ovary with follicles which were retrieved using standard aspiration without flushing. Because of this study design, statistical analysis was carried out using paired T-tests for comparison of flushed and non-flushed ovaries. RESULTS: 111 patients were included with no statistical difference in any outcome if either the left or right ovary was allocated to be flushed. The mean number of oocytes retrieved from the flushed ovary was 9.5 compared to 8.8 in the unflushed ovary (P ¼ 0.13). Mean mature (M2) oocytes retrieved was 7.5 from the flushed ovary, compared to 6.9 from the unflushed ovary (P ¼ 0.12). Blastocysts of good quality obtained from the flushed and unflushed ovaries were 2.5 and 2.1 (P ¼ 0.17). Blastocyst utilization rates from the flushed and unflushed ovaries were 56% and 51% (P ¼ 0.17). CONCLUSIONS: All outcomes studied showed no statistically significant difference between the flushed and unflushed ovary. This is concordant with published studies showing no difference with follicular flushing. This study adds to the literature as uniquely 96.4% of IVF / ICSI cycles included had used GnRH antagonist stimulation and GnRH agonist trigger. This study suggests that follicular flushing does not provide any clinical benefits in patients who are good responders when using an antagonist stimulation cycle with GnRH agonist trigger.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.